Drug Profile
Autologous cultured chondrocyte implant - Vericel
Alternative Names: Autologous cultured chondrocytes; Carticel; Carticel II; Cartilage replacement - SanofiLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Vericel Corporation
- Class Cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Knee injuries
Most Recent Events
- 01 May 2021 Vericel has patent protection for methods of determining the presence of chondrocytes in cell cultures used to produce Carticel in USA and other countries
- 10 May 2017 Autologous cultured chondrocyte implant - Vericel licensed to Innovative Cellular Therapeutics in China, South Korea, Singapore, and other countries in South-East Asia
- 24 Aug 2015 Vericel has patent protection for autologous cultured chondrocyte implant in USA and European Union (Vericel 10-K, August 2015)